Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 07 Mar 2023
People who have had a normal gastrointestinal (GI) biopsy are still at risk of developing inflammatory bowel disease (IBD) over the years...
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
Spouses of Cancer Patients May Be at Increased Risk of Suicide
2.
New protein target discovered for childhood medulloblastomas
3.
How the metastasis of cancer is driven by cellular plasticity.
4.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
5.
Waiting for a Sharp Increase in Prostate Cancer Cases.
1.
Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
4.
Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment
5.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
5.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge